NASDAQ:AMRS - Amyris Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$6.5550 -0.95 (-12.66 %)
(As of 08/17/2018 04:00 PM ET)
Previous Close$6.5550
Today's Range$6.49 - $6.93
52-Week Range$1.97 - $8.08
Volume5.62 million shs
Average Volume670,718 shs
Market Capitalization$389.11 million
P/E Ratio-2.15
Dividend YieldN/A
Beta0.11
Amyris logoAmyris, Inc. provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market. The company also provides renewable solvents, polymers, and lubricants for industrial markets; Biofene ingredients for nutraceuticals and vitamins market; and renewable fuels for transportation fuels markets. It has a collaboration partnership with Total S.A. to produce and commercialize Biofene-based diesel and jet fuels. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.

Receive AMRS News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Industrial organic chemicals
Sub-IndustryOil & Gas Refining & Marketing
SectorBasic Materials
SymbolNASDAQ:AMRS
CUSIP03236M10
Phone510-450-0761

Debt

Debt-to-Equity Ratio-0.35
Current Ratio0.67
Quick Ratio0.62

Price-To-Earnings

Trailing P/E Ratio-2.15
Forward P/E Ratio-4.65
P/E GrowthN/A

Sales & Book Value

Annual Sales$143.45 million
Price / Sales2.30
Cash FlowN/A
Price / CashN/A
Book Value($4.64) per share
Price / Book-1.41

Profitability

EPS (Most Recent Fiscal Year)($3.05)
Net Income$-72,320,000.00
Net Margins-84.53%
Return on EquityN/A
Return on Assets-94.79%

Miscellaneous

Employees414
Outstanding Shares50,370,000
Market Cap$389.11 million

Amyris (NASDAQ:AMRS) Frequently Asked Questions

What is Amyris' stock symbol?

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

When did Amyris' stock split? How did Amyris' stock split work?

Shares of Amyris reverse split before market open on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.

How were Amyris' earnings last quarter?

Amyris Inc (NASDAQ:AMRS) issued its quarterly earnings results on Monday, August, 6th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.30) by $0.08. The biotechnology company earned $24.81 million during the quarter, compared to analysts' expectations of $37.52 million. The company's quarterly revenue was down 3.4% on a year-over-year basis. During the same period last year, the company earned ($1.32) earnings per share. View Amyris' Earnings History.

When is Amyris' next earnings date?

Amyris is scheduled to release their next quarterly earnings announcement on Tuesday, November, 13th 2018. View Earnings Estimates for Amyris.

What price target have analysts set for AMRS?

3 analysts have issued 1-year price targets for Amyris' shares. Their forecasts range from $4.00 to $15.00. On average, they anticipate Amyris' stock price to reach $9.6667 in the next year. This suggests a possible upside of 47.5% from the stock's current price. View Analyst Price Targets for Amyris.

What is the consensus analysts' recommendation for Amyris?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amyris.

What are Wall Street analysts saying about Amyris stock?

Here are some recent quotes from research analysts about Amyris stock:
  • 1. According to Zacks Investment Research, "Amyris INC is an integrated renewable products company applying industrial synthetic biology to genetically modify microorganisms to serve as living factories. Amyris designs these microorganisms to produce defined molecules for use as renewable chemicals and transportation fuels. The Company is engaged in the development of farmesene- a molecule, which serves as the base chemical building block for a wide range of renewable products to replace existing products that are derived from petroleum, plant or animal sources and that may be of lower quality or higher price. Amyris INC is headquartered in Emeryville, CA. " (8/9/2018)
  • 2. HC Wainwright analysts commented, "Turtle Beach reported 2Q18 revenues/EBITDA of $61M/$9.8M, better than consensus of $48M/$3.1M(E) and our $48M/$3.2M(E). The strong sales performance in 2Q (up 218%) was driven by accelerating sell-through and moderate share gain. Management again attributed the outperformance to new demand created by battle royale games such as PUBG and Fortnite. Although it remains to be seen if sell- through momentum can sustain after the coming holiday season, HEAR has already gone through a meaningful transformation with a healthier balance sheet and an expanded installed headset base, both setting up the company well for long-term investments and growth. We raise our FY18 estimates and price target to $35 (was $31). Reiterate Outperform." (8/7/2018)

Who are some of Amyris' key competitors?

Who are Amyris' key executives?

Amyris' management team includes the folowing people:
  • Mr. John G. Melo, Pres, CEO & Director (Age 52)
  • Ms. Kathleen Valiasek, Chief Financial Officer (Age 54)
  • Mr. Eduardo Alvarez, Chief Operating Officer (Age 54)
  • Ms. Nicole Kelsey, Gen. Counsel & Sec. (Age 51)
  • Dr. Joel R. Cherry, Pres of R&D (Age 57)

Has Amyris been receiving favorable news coverage?

News stories about AMRS stock have been trending somewhat positive recently, Accern Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Amyris earned a media and rumor sentiment score of 0.17 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 44.63 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. View Recent Headlines for Amyris.

Who are Amyris' major shareholders?

Amyris' stock is owned by many different of retail and institutional investors. Top institutional investors include TEMASEK HOLDINGS (PRIVATE) LTD (8.90%), BlackRock Inc. (3.41%), FMR LLC (0.79%), Millennium Management LLC (0.55%), Ardsley Advisory Partners (0.25%) and Bank of New York Mellon Corp (0.21%). Company insiders that own Amyris stock include (Mauritius) Pte Ltd Maxwell, John Melo and Patrick Y Yang. View Institutional Ownership Trends for Amyris.

Which institutional investors are selling Amyris stock?

AMRS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC. Company insiders that have sold Amyris company stock in the last year include (Mauritius) Pte Ltd Maxwell and John Melo. View Insider Buying and Selling for Amyris.

Which institutional investors are buying Amyris stock?

AMRS stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Engineers Gate Manager LP, Bank of New York Mellon Corp, Schwab Charles Investment Management Inc., B. Riley Financial Inc., Millennium Management LLC, Renaissance Technologies LLC and Ardsley Advisory Partners. View Insider Buying and Selling for Amyris.

How do I buy shares of Amyris?

Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amyris' stock price today?

One share of AMRS stock can currently be purchased for approximately $6.5550.

How big of a company is Amyris?

Amyris has a market capitalization of $389.11 million and generates $143.45 million in revenue each year. The biotechnology company earns $-72,320,000.00 in net income (profit) each year or ($3.05) on an earnings per share basis. Amyris employs 414 workers across the globe.

How can I contact Amyris?

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-450-0761 or via email at [email protected]


MarketBeat Community Rating for Amyris (NASDAQ AMRS)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  207 (Vote Outperform)
Underperform Votes:  255 (Vote Underperform)
Total Votes:  462
MarketBeat's community ratings are surveys of what our community members think about Amyris and other stocks. Vote "Outperform" if you believe AMRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.